Tysabri - Therapeutic Monoclonal Antibody (MAb) for the Treatment of Multiple Sclerosis, No Country
Key Data:
Drug (brand / generic)
Tysabri (natalizumab)
Company / Licensee
Elan Pharmaceuticals/ Biogen
Therapy Class
Selective Adhesion-Molecule Inhibitor
Product Description
Alpha-4 antagonist
Current Indication
Treatment of multiple sclerosis
Market Sector
CNS
Development Status
Launched US end 2004; recalled February 2005; reintroduced July 2006. Approved Europe
